Pilot Study of Induction Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A) in Patients With Locally Advanced Head and Neck Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab; Cisplatin; Docetaxel
- Indications Head and neck cancer; Nasopharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 12 Feb 2014 New trial record